2,114
Views
2
CrossRef citations to date
0
Altmetric
Mental Health

The impact of lurasidone on functioning and indirect costs in adults with bipolar depression: a post-hoc analysis

, , , , , & show all
Pages 152-159 | Received 07 Dec 2021, Accepted 13 Jan 2022, Published online: 03 Feb 2022

References

  • Carvalho AF, Firth J, Vieta E. Bipolar disorder. N Engl J Med. 2020;383(1):58–66.
  • Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–251.
  • Bessonova L, Ogden K, Doane MJ, et al. The economic burden of bipolar disorder in the United States: a systematic literature review. Clinicoecon Outcomes Res. 2020;12:481–497.
  • MacQueen GM, Young LT, Joffe RT. A review of psychosocial outcome in patients with bipolar disorder. Acta Psychiatr Scand. 2001;103(3):163–170.
  • Léda-Rêgo G, Bezerra-Filho S, Miranda-Scippa Â. Functioning in euthymic patients with bipolar disorder: a systematic review and Meta-analysis using the functioning assessment short test. Bipolar Disord. 2020;22(6):569–581.
  • Grande I, Berk M, Birmaher B, et al. Bipolar disorder. Lancet. 2016;387(10027):1561–1572.
  • Cloutier M, Greene M, Guerin A, et al. The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord. 2018;226:45–51.
  • Baldessarini RJ, Vázquez GH, Tondo L. Bipolar depression: a major unsolved challenge. Int J Bipolar Disord. 2020;8(1):1.
  • Zimmerman M, Galione JN, Chelminski I, et al. Sustained unemployment in psychiatric outpatients with bipolar disorder: frequency and association with demographic variables and comorbid disorders. Bipolar Disord. 2010;12(7):720–726.
  • Forte A, Baldessarini RJ, Tondo L, et al. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. J Affect Disord. 2015;178:71–78.
  • Latuda (lurasidone) [package insert]. Marlborough (MA): Sunovion Parmaceuticals Inc.; 2018.
  • Loebel A, Citrome L. Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. BJPsych Bull. 2015;39(5):237–241.
  • Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160–168.
  • Sheehan D. The anxiety disease. New York (NY): Scribners; 1983.
  • Rajagopalan K, Bacci ED, Wyrwich KW, et al. The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial. Int J Bipolar Disord. 2016;4(1):7.
  • Ketter TA, Sarma K, Silva R, et al. Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study. Depress Anxiety. 2016;33(5):424–434.
  • Arbuckle R, Frye MA, Brecher M, et al. The psychometric validation of the Sheehan Disability Scale (SDS) in patients with bipolar disorder. Psychiatry Res. 2009;165(1–2):163–174.
  • Zhou ZY, Koerper MA, Johnson KA, et al. Burden of illness: direct and indirect costs among persons with hemophilia a in the United States. J Med Econ. 2015;18(6):457–465.
  • Benson C, Singer D, Carpinella CM, et al. The health-related quality of life, work productivity, healthcare resource utilization, and economic burden associated with levels of suicidal ideation among patients self-reporting moderately severe or severe major depressive disorder in a national survey. NDT. 2021;17:111–123.
  • Bureau of Labor Statistics. Employer costs for employee compensation - March 2021. Washington (DC): US Department of Labor; 2021.
  • Cohen J. Statistical power analysis for the behavioral sciences. New York (NY): Routledge Academic; 1988.
  • Chevance A, Ravaud P, Tomlinson A, et al. Identifying outcomes for depression that matter to patients, informal caregivers, and health-care professionals: qualitative content analysis of a large international online survey. Lancet Psychiatry. 2020;7(8):692–702.
  • Fan Q, Dembek C, Divino V, et al. The impact of lurasidone on health-related quality of life in patients with bipolar depression: a post-hoc analysis of a 6-month open-label extension study [Abstract]. NEI Conference. 2021 Nov 4-7; Colorado Springs, CO.
  • Laxman KE, Lovibond KS, Hassan MK. Impact of bipolar disorder in employed populations. Am J Manag Care. 2008;14(11):757–764.
  • Kleinman NL, Brook RA, Rajagopalan K, et al. Lost time, absence costs, and reduced productivity output for employees with bipolar disorder. J Occup Environ Med. 2005;47(11):1117–1124.
  • Kato T, Ishigooka J, Miyajima M, et al. Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry Clin Neurosci. 2020;74(12):635–644.
  • Suttajit S, Srisurapanont M, Maneeton N, et al. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther. 2014;8:827–838.
  • Vieta E, Calabrese JR, Whelan J, et al. The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial. Curr Med Res Opin. 2021;37(9):1635–1643.
  • Gitlin MJ, Miklowitz DJ. The difficult lives of individuals with bipolar disorder: a review of functional outcomes and their implications for treatment. J Affect Disord. 2017;209:147–154.
  • Cotrena C, Damiani Branco L, Milman Shansis F, et al. Influence of modifiable and non-modifiable variables on functioning in bipolar disorder: a path analytical study. Int J Psychiatry Clin Pract. 2020;24(4):398–406.